Aspirin Shortages for Cardiovascular Care Expected to Last Until 2027

Confirmed Shortages of Key Aspirin Dosages

The French National Agency for Medicines and Health Products Safety (ANSM) has confirmed prolonged shortages of 75 mg and 100 mg aspirin tablets used to treat cardiovascular conditions, with supply issues expected to persist at least until early 2027, according to franceinfo. The agency cited production and distribution challenges as the primary causes, though specific details remain under investigation.

Supply Chain Disruptions Cited as Primary Cause

The ANSM attributed the shortages to “complex supply chain disruptions,” including raw material availability and manufacturing delays, as reported by Sud Ouest. While the agency did not specify exact reasons, it emphasized that the issue affects generic aspirin formulations critical for preventing heart attacks and strokes. The shortages have been particularly acute for gastro-resistant aspirin tablets, which are designed to reduce stomach irritation.

Patients Face Prescription Challenges and Stockouts

Healthcare providers across France have reported increased difficulty in prescribing standard aspirin doses, with some pharmacies experiencing complete stockouts. Le Moniteur des pharmacies noted “severe supply tensions” for 75 mg and 100 mg formulations, prompting the ANSM to authorize substitutions with alternative antiplatelet medications. The agency stated that “patients should not discontinue their treatment but consult their healthcare provider for appropriate alternatives.”

Regulator Approves Substitutions, Urges Production Prioritization

In response to the crisis, the ANSM issued guidelines allowing pharmacists to substitute aspirin with other approved medications, such as clopidogrel, under medical supervision. The agency also urged manufacturers to prioritize production of these critical formulations. “We are working closely with pharmaceutical companies to resolve these shortages as quickly as possible,” an ANSM spokesperson said in a statement.

Public Health Experts Warn of Treatment Risks

Aspirin is a cornerstone of secondary prevention for cardiovascular diseases, with millions of patients relying on daily low-dose regimens. The prolonged shortages risk disrupting treatment for high-risk individuals, potentially increasing hospitalization rates. Public health experts have called for greater transparency from manufacturers and regulators to prevent similar crises in the future.

Regulators Vow Ongoing Monitoring, No Clear Timeline

The ANSM has not provided a definitive timeline for resolving the shortages but reiterated that the situation is under active monitoring. Patients are advised to maintain open communication with their healthcare providers and report any persistent supply issues to local pharmacies. The agency also plans to publish a comprehensive update on the matter by late 2026.